{"id":27355,"date":"2022-07-29T00:06:00","date_gmt":"2022-07-28T16:06:00","guid":{"rendered":"https:\/\/flcube.com\/?p=27355"},"modified":"2025-02-20T00:09:27","modified_gmt":"2025-02-19T16:09:27","slug":"cosmo-pharmas-winlevi-cream-secures-greater-china-licensing-deal-with-3sbio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=27355","title":{"rendered":"Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio"},"content":{"rendered":"\n

Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN<\/a>) and China’s 3SBio Inc. (HKG: 1530<\/a>) have signed a licensing agreement for Cosmo’s Winlevi (clascoterone) cream 1%, a topical therapy for acne. 3SBio will hold development and commercialization rights for Winlevi in Greater China, including mainland China, Hong Kong, Taiwan, and Macao.<\/p>\n\n\n\n

Deal Details<\/strong>
The agreement includes a first-refusal option for 3SBio to acquire Greater China rights to Breezula (clascoterone 7.5% solution), currently in Phase III development for alopecia. Cosmo will receive an upfront payment of USD 6.5 million, with potential milestones totaling up to USD 63.5 million and royalties on net sales.<\/p>\n\n\n\n

Drug Profile<\/strong>
Winlevi was approved by the US FDA in August 2020 to treat acne vulgaris in patients aged 12 and older. The drug, developed by Cosmo spin-off Cassiopea SpA, is an androgen receptor inhibitor targeting the androgen component of acne in sebaceous glands. It was the first acne drug with a new mechanism of action in 40 years.<\/p>\n\n\n\n

Market Context<\/strong>
Despite acne affecting up to 100 million people annually in China, treatment rates remain low compared to Western markets. The partnership aims to address this unmet need by introducing Winlevi to Greater China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China’s 3SBio Inc. (HKG: 1530) have signed a…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[116,2683,1061,3716],"class_list":["post-27355","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-3sbio","tag-cosmo-pharmaceuticals","tag-hkg-1530","tag-swx-copn"],"yoast_head":"\nCosmo Pharma's Winlevi Cream Secures Greater China Licensing Deal with 3SBio - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China's 3SBio Inc. (HKG: 1530) have signed a licensing agreement for Cosmo's Winlevi (clascoterone) cream 1%, a topical therapy for acne. 3SBio will hold development and commercialization rights for Winlevi in Greater China, including mainland China, Hong Kong, Taiwan, and Macao.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=27355\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cosmo Pharma's Winlevi Cream Secures Greater China Licensing Deal with 3SBio\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=27355\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-28T16:06:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-19T16:09:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27355#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27355\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio\",\"datePublished\":\"2022-07-28T16:06:00+00:00\",\"dateModified\":\"2025-02-19T16:09:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27355\"},\"wordCount\":202,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"3SBio\",\"Cosmo Pharmaceuticals\",\"HKG: 1530\",\"SWX: COPN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=27355#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27355\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=27355\",\"name\":\"Cosmo Pharma's Winlevi Cream Secures Greater China Licensing Deal with 3SBio - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-07-28T16:06:00+00:00\",\"dateModified\":\"2025-02-19T16:09:27+00:00\",\"description\":\"Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China's 3SBio Inc. (HKG: 1530) have signed a licensing agreement for Cosmo's Winlevi (clascoterone) cream 1%, a topical therapy for acne. 3SBio will hold development and commercialization rights for Winlevi in Greater China, including mainland China, Hong Kong, Taiwan, and Macao.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27355#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=27355\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=27355#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cosmo Pharma's Winlevi Cream Secures Greater China Licensing Deal with 3SBio - Insight, China's Pharmaceutical Industry","description":"Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China's 3SBio Inc. (HKG: 1530) have signed a licensing agreement for Cosmo's Winlevi (clascoterone) cream 1%, a topical therapy for acne. 3SBio will hold development and commercialization rights for Winlevi in Greater China, including mainland China, Hong Kong, Taiwan, and Macao.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=27355","og_locale":"en_US","og_type":"article","og_title":"Cosmo Pharma's Winlevi Cream Secures Greater China Licensing Deal with 3SBio","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=27355","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-07-28T16:06:00+00:00","article_modified_time":"2025-02-19T16:09:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=27355#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=27355"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio","datePublished":"2022-07-28T16:06:00+00:00","dateModified":"2025-02-19T16:09:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=27355"},"wordCount":202,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["3SBio","Cosmo Pharmaceuticals","HKG: 1530","SWX: COPN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=27355#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=27355","url":"https:\/\/flcube.com\/?p=27355","name":"Cosmo Pharma's Winlevi Cream Secures Greater China Licensing Deal with 3SBio - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-07-28T16:06:00+00:00","dateModified":"2025-02-19T16:09:27+00:00","description":"Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China's 3SBio Inc. (HKG: 1530) have signed a licensing agreement for Cosmo's Winlevi (clascoterone) cream 1%, a topical therapy for acne. 3SBio will hold development and commercialization rights for Winlevi in Greater China, including mainland China, Hong Kong, Taiwan, and Macao.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=27355#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=27355"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=27355#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27355"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27355\/revisions"}],"predecessor-version":[{"id":27356,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/27355\/revisions\/27356"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}